ALI revenues decline in Q3Purchasing delays related to the year 2000 problem weighed down financial results at ultrasound miniPACS firm ALI Technologies. During its fiscal third quarter (end-June), ALI posted revenues of $3.7 million (U.S.), an
Purchasing delays related to the year 2000 problem weighed down financial results at ultrasound miniPACS firm ALI Technologies. During its fiscal third quarter (end-June), ALI posted revenues of $3.7 million (U.S.), an increase of 7% over the same period in 1998, but a decrease of 22% from second-quarter 1999 (end-March). The company attributed the decrease to Y2K software conformance issues its clients are facing.
During the quarter, the company incurred a net loss of $178,302, and sustained a charge of $231,058 for restruct-uring costs related to its purchase of Olicon Imaging Systems (PNN 7/99). ALI reported that its integration of Olicons image management business is almost complete.
ALI also announced that two multimodality sites are in clinical operation under its introductory beta site pilot program (PNN 12/98), which will be completed in the fall. In addition, the Vancouver, BC-based company has purchase commitments for three additional multimodality systems from Pitt County Memorial Hospital in Greenville, NC, the University of California, Los Angeles Santa Monica Clinic in Santa Monica, CA, and the Texas Health System-Arlington Memorial South Medical Center in Dallas.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.